research use only
Cat.No.: F4977
| Dilution |
|---|
|
| Application |
|---|
| WB, FCM, ELISA |
| Reactivity |
|---|
| Human |
| Source |
|---|
| Rabbit Monoclonal Antibody |
| Storage Buffer |
|---|
| PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3 |
| Storage (from the date of receipt) |
|---|
| -20°C (avoid freeze-thaw cycles), 2 years |
| Predicted MW Observed MW |
|---|
| 68 kDa 51-71 kDa |
| *Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization. |
| Positive Control | Jurkat cells; SGC-7901 cells; A549 cells |
|---|---|
| Negative Control |
| WB |
|---|
Experimental Protocol:
Sample preparation
1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA Lysis Buffer (containing Protease Inhibitor Cocktail),and homogenize the tissue at a low temperature. 2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min. 3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA Lysis Buffer (containing Protease Inhibitor Cocktail) and put the sample on ice for 5 min. 4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
5. Remove a small volume of lysate to determine the protein concentration;
6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
Electrophoretic separation
1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 10%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations 2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
Transfer membrane
1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip"; 4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications Recommended conditions for wet transfer: 200 mA, 120 min. ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
Block
1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
2. Incubate the film in the blocking solution for 1 hour at room temperature;
3. Wash the film with TBST for 3 times, 5 minutes each time.
Antibody incubation
1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:2000), gently shake and incubate with the film at 4°C overnight; 2. Wash the film with TBST 3 times, 5 minutes each time;
3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
Antibody staining
1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system. |
| Specificity |
|---|
| ACSF2 Antibody [F15E3] detects endogenous levels of total ACSF2 protein. |
| Subcellular Location |
|---|
| Mitochondrion |
| Uniprot ID |
|---|
| Q96CM8 |
| Clone |
|---|
| F15E3 |
| Synonym(s) |
|---|
| ACSF2; Medium-chain acyl-CoA ligase ACSF2, mitochondrial; UNQ493/PRO1009 |
| Background |
|---|
| ACSF2 (acyl-CoA synthetase family member 2) is a mitochondrial matrix enzyme that catalyzes the activation of medium-chain fatty acids into acyl-CoA thioesters, a crucial step for β-oxidation and maintaining lipid homeostasis. It possesses a canonical AMP-binding superfamily architecture, including an N-terminal mitochondrial targeting sequence that is cleaved upon import, an ATP-grasp domain responsible for Mg-ATP binding, an A10-like subdomain forming the substrate-binding cleft for fatty acid interaction, and a C-terminal dimerization domain that enables obligatory homodimerization. ACSF2 operates via a two-step ping-pong mechanism, where ATP thioesterification forms an acyl-AMP intermediate followed by nucleophilic displacement by the CoA thiol to generate acyl-CoA and AMP, with a marked specificity for medium-chain fatty acids. This enzyme supports mitochondrial β-oxidation by enabling CPT1-independent import of medium-chain fatty acids, bypassing carnitine shuttle limitations. Deficiency of ACSF2 leads to combined malonic and methylmalonic aciduria (CMAMMA), resulting in the accumulation of dicarboxylic acids due to impaired fatty acid catabolism and deficits in protein lipoylation, which are essential for mitochondrial enzyme complex stability. Somatic overexpression of ACSF2 is associated with non-alcoholic fatty liver disease and hepatocellular carcinoma through dysregulated hepatic VLDL secretion and increased lipid droplet accumulation. |
| References |
|---|
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.